Category: Biotech

3 Stocks That Are Ridiculously Cheap Right Now

With the market steadily pushing above and beyond its all-time highs, it’s becoming increasingly difficult to find stocks with compelling valuations. With this in mind, we asked three of our contributors which stocks they think are still bargains that might be worth buying right now.

Daily Dividend Report: PBA, PLCE, AMGN, SPLS, VGR

Pembina Pipeline announced today that its Board of Directors declared a common share cash dividend for March 2017 of $0.16 per share to be paid, subject to applicable law, on April 15, 2017 to shareholders of record on March 25, 2017. The Children’s Place, the largest pure-play children’s specialty apparel retailer in North America, today announced that its Board of Directors has approved a new $250 million share repurchase program and has increased the Company’s quarterly dividend to $0.40 per share from $0.20 per share.

Wednesday’s ETF with Unusual Volume: XT

The iShares Exponential Technologies ETF is seeing unusually high volume in afternoon trading Wednesday, with over 637,000 shares traded versus three month average volume of about 73,000. Shares of XT were trading flat on the day.

Is This The Best Biotech Play for 2017?

Last year, a political spotlight on drug pricing policies threatened the entire industry. Scandals at Mylan and Valeant Therapeutics did damage to the entire sector, sending the share prices of many biotech companies down.

Dow Chemical Subsidiary Must Pay $456 Million Award to Bayer

A federal appeals court ruled that a Dow Chemical subsidiary must pay $456 million for violating a patent licensing agreement with Bayer AG , affirming a lower court ruling. Jim Cramer ponders what motivates someone to call a market top, and talks about how the market could be playing ‘The Price Is Wrong.’

Bayer Sells $1.5 Billion in Covestro Stock to Trim Debt

Bayer AG sold 1.46 billion euros worth of shares in plastics maker Covestro AG to gain financial leeway as it seeks clearance for its $66 billion takeover of agriculture giant Monsanto Co. Bayer sold 22 million shares for 66.50 euros each, paring its stake in its former division to 53.3 percent, the German conglomerate said in a statement on Wednesday.

Biotech Premarket Movers: Impax, Clearside Biomedical, Mylan

Shares of Impax Laboratories were down 19% to $11.50 in premarket trading on Wednesday after the company reported results and said it is not issuing 2017 guidance for total revenue and EPS because of ongoing revenue volatility in its generics unit. The Fort Washington, Pa.-based firm reported fourth-quarter adjusted earnings per share of 16 cents on revenue of $198.4 million.

Is Illumina On The Verge of a Breakout?

Illumina has been tracing out a narrow consolidation pattern for the last seven weeks. Yesterday’s impressive 4.25% gain, which was the second-best performance in the Nasdaq 100, may soon spark an end to this bullish pennant formation with a fresh rally leg.

Gilead and ‘Good News’ Make A Rare, Joint Appearance at HIV Conference

With sales of its hepatitis C drugs falling and an oncology pipeline that has largely disappointed, bictegravir is vitally important for Gilead to defend and grow its dominant HIV franchise. Bictegravir, the company’s next-generation integrase inhibitor, suppressed the HIV virus in newly diagnosed patients better than dolutegravir, a similar, rival drug from GlaxoSmithKline , according to results from a mid-stage clinical trial announced Monday night.

Why Sage Therapeutics Jumped Today

Sage Therapeutics announced top-lineresults froma Phase 2 clinical trial study of SAGE-217, the company’s orally administereddrug that is being researched as a hopeful treatment of major depressive disorder . Data from the trial showed that SAGE-217 met the study’s primary endpoint, which was to evaluate that the drug was safe and well-tolerated by patients.

Teva Said to Consider Options for Branded Generics Unit

Israeli drugmaker Teva Pharmaceutical Industries Ltd. is weighing options including a sale of its branded generics products business as it works to reduce debt, according to people familiar with the matter. The business could be valued at several billion dollars, and Teva may also consider spinning off the unit, the people said, asking not to be identified because the deliberations are private.

Why Intercept Pharmaceuticals’ Latest News Caused the Stock to Jump

So when the companyannounced on Friday morning that it was making a significant change to its late-stage clinical study of obeticholic acid in treating NASH, investors were eager to find out what’s going on. Intercept’s phase 3 REGENERATE clinical trial initially had two co-primary endpoints: fibrosis improvement with no worsening of NASH and NASH resolution with no worsening of fibrosis.

Allergan: Cramer’s Top Takeaways

Did you miss last night’s “Mad Money” on CNBC ? If so, here are some of Jim Cramer’s top takeaways. In his third and final “Executive Decision” segment, Cramer spoke with Brent Saunders, chairman and CEO of Allergan , which today reported a 14-cents-a-share earnings beat on a 7% rise in revenues, but still trades at just 15 times earnings.

Gilead’s Biggest Blockbusters Are Fading Fast, Biotech Warns

Gilead Sciences Inc.’s massive hepatitis C franchise is fading, the company warned Tuesday, projecting that sales this year could be just two-thirds of what investors had been expecting. Revenue from the company’s drugs for the viral infection will be $7.5 billion to $9 billion in 2017, Gilead said in a statement.

Earnings Preview: GlaxoSmithKline Likely to See Currency Boost; Advair Sales in Focus

GlaxoSmithKline reports fourth-quarter earnings Wednesday, with investors looking for guidance on the fate of its key Advair drug and the recent pace of organic growth for new products sales. GlaxoSmithKline Plc reports fourth-quarter earnings Wednesday, with investors looking for guidance on the fate of its key Advair drug in the U.S. and the recent pace of organic growth for new products sales.

Teva Loses CEO, Leaving Investors to Guess What’s Next

Teva Pharmaceutical Industries Ltd. announced the departure of its chief executive officer after just three years and said it would undertake a thorough review of its business, leaving the world’s largest generic-drug maker without a permanent leader following lowered profit forecasts that sent the share price plunging. CEO Erez Vigodman has stepped down, and Chairman Yitzhak Peterburg will hold the job on an interim basis while a search is conducted for a successor, the Petach Tikva, Israel-based company said in a statement late Monday.

Teva Searches for a New CEO

The Jerusalem-based pharmaceutical company named Dr. Yitzhak Peterburg as interim CEO after Erez Vigodman stepped down following a mutual agreement with the board. Teva Pharmaceutical is looking for a new CEO after Erez Vigodman stepped down following a mutual agreement with the board, the company said Monday.

California Sues Teva, Allergan for Allegedly Blocking Generic Competition to Lidoderm

The state of California has filed a civil suit against units of drugmakers Teva and Allergan , for allegedly obstructing generic competition to Lidoderm transdermal patches. The suit, filed in federal court in San Francisco, alleges a “pay-for-delay” deal between the companies and Endo Pharmaceuticals, which already had its Lidoderm product on the market and had made $825 million off of it in 2011.

Why The Medicines Company Rocketed Higher Today

Amgen’s PCSK9 inhibitor Repatha “significantly” reduced the risk of cardiovascular events — heart attacks, strokes, and the like — compared to placebo. Investors will have to wait until the American College of Cardiology meeting next month to find out how significant the reduction was.